What Is the Medical Definition of Osteoarthritis?

Osteoarthritis is medically defined as a disorder of movable joints characterized by cell stress and breakdown of the tissue between bones, driven by a failed repair response that involves the body’s innate immune system. That single sentence, drawn from a major 2015 consensus effort, replaced decades of looser descriptions that treated the condition as simple cartilage erosion. The modern definition matters because it reframes osteoarthritis as a disease of the entire joint, not just worn-out cushioning, and that reframing is changing how the condition is diagnosed, studied, and treated.

How the Formal Definition Took Shape

For most of the twentieth century, osteoarthritis was described in textbooks as “degenerative joint disease,” a label implying that cartilage simply wore down with age and use. The problem was that this description did not capture what researchers were actually finding in diseased joints. In 2015, a working group published a call for standardized definitions, proposing language that has since become widely cited. Their draft defines osteoarthritis as a disorder “characterized by cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses including pro-inflammatory pathways of innate immunity.” The disease, they wrote, “manifests first as a molecular derangement (abnormal joint tissue metabolism) followed by anatomic, and/or physiologic derangements (characterized by cartilage degradation, bone remodeling, osteophyte formation, joint inflammation and loss of normal joint function), that can culminate in illness.”¹

Two ideas in that definition are worth unpacking. First, it establishes a sequence: molecular changes come before anything visible on an X-ray. A joint can be in the early stages of osteoarthritis long before any scan shows damage. Second, it separates the disease process from the illness. Not everyone whose joint tissues are changing will feel pain or lose function. That distinction matters for diagnosis, because it explains why X-ray findings and patient symptoms so often disagree.

What Happens Inside a Joint With Osteoarthritis

Cartilage breakdown is the most recognized feature, but it is only one part of what goes wrong. Healthy cartilage depends on a scaffold of proteins, primarily collagen and a molecule called aggrecan, that gives it both structure and shock-absorbing ability. In osteoarthritis, enzymes begin chewing through that scaffold. Research on genetically modified mice has confirmed that two enzymes in particular play central roles: one (ADAMTS-5) targets aggrecan, and another (MMP-13) targets collagen.² The damage begins at the microscopic level. A 2025 study demonstrated that these enzymes attack the thin envelope surrounding each cartilage cell before spreading to the wider tissue. Once that envelope breaks down, the cells inside lose their ability to sense and respond to mechanical forces properly, which accelerates the deterioration.³

Below the cartilage sits subchondral bone, and it does not sit idle while the cartilage above it frays. Abnormal mechanical stresses cause tiny fractures in this bone layer, triggering a remodeling process that leads to thickened, sclerotic bone and the growth of bony spurs called osteophytes. As cartilage cracks open, joint fluid seeps into the underlying bone along with inflammatory molecules, amplifying the damage.⁴ Meanwhile, the synovial lining that encases the joint can become inflamed, and the joint capsule itself may thicken. The upshot is that osteoarthritis involves every structure in the joint, not just the cartilage.

Why “Wear and Tear” Is Misleading

The old “wear and tear” framing implied that osteoarthritis was an inevitable consequence of mechanical use. Accumulating research has pushed the definition firmly away from that idea by demonstrating that chronic, low-grade inflammation is a key driver. This inflammation looks different from what occurs in autoimmune forms of arthritis: it is subtler, driven by the innate immune system rather than by antibodies attacking the body’s own tissues.⁵ But it is persistent, and it contributes to cartilage loss, bone remodeling, and pain in ways that purely mechanical wear cannot explain.

Recent reviews have gone so far as to call osteoarthritis a low-grade inflammatory disease, arguing that this reclassification should guide how the condition is treated.⁶ Inflammatory markers detected in joint tissues by modern imaging correlate with how severe the disease becomes and how fast it progresses.⁷ This does not mean mechanics are irrelevant. Injury, joint misalignment, and repetitive loading still contribute. But they do so in part by triggering inflammatory cascades rather than simply grinding cartilage away.

How Osteoarthritis Is Diagnosed

There is no single blood test for osteoarthritis. Diagnosis typically relies on a combination of clinical features and imaging, and the criteria used can vary depending on who wrote the guidelines. Three major sets of clinical criteria are commonly applied in primary care: those from the European League Against Rheumatism, the American College of Rheumatology, and the UK’s National Institute for Health and Care Excellence. A large cross-sectional study comparing all three in over 13,000 patients found that the proportion of people classified as having knee osteoarthritis differed depending on which set was used.⁸ In practice, most clinicians look for persistent joint pain that worsens with activity, morning stiffness lasting less than about 30 minutes, and crepitus (that grinding feeling when you move the joint).

Plain X-rays remain the most common imaging tool. The widely used Kellgren-Lawrence grading system classifies osteoarthritis by the presence of osteophytes and narrowing of the space between bones where cartilage should be. Generally, a grade of 2 or above, meaning definite bone spurs with possible narrowing of the joint space, is considered radiographic osteoarthritis.⁹ MRI offers a more detailed look and can reveal changes invisible on X-ray, such as bone marrow lesions, which are increasingly recognized as dynamic markers that correlate with pain severity and structural worsening.¹⁰ Ultrasound is used in some settings to quickly check whether the problem might actually be an inflammatory arthritis rather than osteoarthritis.¹¹

When Pain and X-Rays Do Not Match

One of the most frustrating aspects of osteoarthritis, for patients and doctors alike, is that pain levels often have little correlation with what imaging shows. Some people with badly damaged joints on X-ray report minimal pain. Others have severe, disabling pain yet their X-rays look nearly normal. A study using quantitative sensory testing found that patients reporting high pain without corresponding structural damage showed signs of heightened nervous-system sensitivity at body sites far from the affected knee, suggesting that their central nervous system had become amplifying pain signals. Meanwhile, patients with extensive joint damage but low pain appeared to be less sensitive overall, as if their nervous systems were buffering the signals.¹²

This discordance reinforces the idea embedded in the modern definition: osteoarthritis is not just a disease of cartilage. Soft tissues, the synovial lining, and even the nervous system all participate. As one research group put it, the condition involves the whole joint and eventually leads to joint failure, much the way heart disease involves the entire cardiovascular system and can lead to heart failure.¹³ For patients, the practical takeaway is that a “clean” X-ray does not mean nothing is wrong, and a dramatic-looking X-ray does not necessarily predict how much pain you will have.

Risk Factors the Definition Helps Explain

Redefining osteoarthritis as an inflammatory, whole-joint disease clarifies why certain risk factors matter beyond their mechanical effects. Obesity is a major driver of knee and hip osteoarthritis, and for a long time the explanation was straightforward: heavier bodies put more force through the joints. That is true, but it is not the full story. Research now highlights that obesity contributes through systemic inflammation as well. Fat tissue, especially abdominal fat, releases inflammatory molecules called adipokines that circulate through the body and affect joint tissues directly.¹⁴ This is why osteoarthritis also occurs in hand joints, which bear almost no body weight. The metabolic angle is strong enough that some researchers have argued osteoarthritis should be viewed partly as a metabolic disease, with abnormal blood lipids, insulin resistance, and adipokine signaling all feeding the process.¹⁵

A separate line of evidence using genetic analysis methods has confirmed that obesity contributes to hip osteoarthritis through both weight-bearing and non-weight-bearing pathways, including local inflammation.¹⁶ Age, sex, and genetics also remain important, but none of these fully explains the disease on its own.

Post-Traumatic Osteoarthritis

Joint injuries create a distinct pathway to osteoarthritis, and this subset has its own label: post-traumatic osteoarthritis. Tearing the anterior cruciate ligament in the knee is one of the clearest triggers. The risk of developing osteoarthritis in that knee rises substantially, whether or not the ligament is surgically repaired. The injury sets off a cascade involving structural instability, inflammatory mediators, altered loading, and changes in how the surrounding muscles control the joint.¹⁷

Because there is a clear moment when the disease process begins, post-traumatic osteoarthritis has become an important focus for research into early intervention. Mouse studies have shown that the amount of weight a damaged joint bears after injury affects how quickly cartilage cells die and how severely the joint deteriorates. Limbs bearing more load after ligament injury developed worse cartilage damage and stiffer tissue compared to limbs bearing less load.¹⁸ The implication for people recovering from knee injuries is that managing loading patterns matters, although the ideal approach in humans is still being worked out.

Distinguishing Osteoarthritis From Other Joint Diseases

One reason a precise medical definition matters is that the wrong diagnosis leads to the wrong treatment. Rheumatoid arthritis, gout, and joint infections can all produce pain and swelling in the same joints osteoarthritis favors. In rheumatoid arthritis, the immune system attacks the joint lining aggressively, typically causing symmetrical joint involvement, prolonged morning stiffness, and elevated inflammatory markers in the blood. Gout results from urate crystal deposits and tends to flare suddenly. Septic arthritis, a bacterial joint infection, is a medical emergency. One study found that measuring levels of a blood marker called procalcitonin in both blood and joint fluid could help distinguish septic arthritis from osteoarthritis, rheumatoid arthritis, and gout, with low procalcitonin levels effectively ruling out infection.¹⁹

Because the low-grade inflammation in osteoarthritis can sometimes produce mild swelling and warmth, it occasionally mimics inflammatory arthritis early on. Imaging is often the tiebreaker. X-rays showing osteophytes without the joint erosions typical of rheumatoid arthritis point toward osteoarthritis, and ultrasound can quickly flag features of inflammatory disease.

When Osteoarthritis Affects Multiple Joints

Osteoarthritis commonly appears in the knees, hips, hands, and spine, but it does not always stay in one joint. Generalized osteoarthritis, where multiple joint groups are affected, is a recognized pattern. In a large family-based study of people with hand osteoarthritis confirmed on X-ray, about half also had radiographic osteoarthritis of the knee and the spine, while roughly a quarter had it in the hip.²⁰ This clustering supports the idea that systemic factors, whether genetic, metabolic, or inflammatory, drive the disease in many cases rather than purely local mechanical factors.

The Search for Disease-Modifying Treatments

No drug approved to date can reverse or halt the structural progression of osteoarthritis. Current treatments manage symptoms: pain relievers, anti-inflammatory medications, physical therapy, and eventually joint replacement. The regulatory concept of a disease-modifying osteoarthritis drug, sometimes abbreviated DMOAD, has been defined by agencies including the FDA and the European Medicines Agency. A DMOAD would need to demonstrate that it slows structural joint damage, typically measured as narrowing of the joint space on X-rays, and that this structural benefit translates into a clinical benefit the patient can feel.²¹

The FDA has recognized osteoarthritis as a “serious condition” under its accelerated approval regulations, which means experimental drugs could potentially gain initial approval based on surrogate markers like imaging biomarkers, provided that their effect on symptoms is confirmed afterward.²² Blood and urine markers tied to bone and cartilage turnover are being investigated as potential ways to track disease progression without waiting years for X-ray changes to accumulate. Early work suggests that short-term changes in certain bone-turnover markers may predict worsening bone marrow lesions on MRI.²³

Despite decades of effort, the list of failed DMOAD candidates is long. A review of past failures identified three lessons reshaping current strategy: injecting drugs directly into the joint may be more effective than systemic pills; osteoarthritis is not a single disease but a collection of subtypes, or phenotypes, that may each need a different treatment; and regulatory agencies are now offering more nuanced biomarker guidance to help trials succeed.²⁴ The recognition that one definition covers many different biological subtypes is arguably the biggest shift in thinking. Two people meeting the same diagnostic criteria may have very different underlying biology, and treating them identically has been a recurring reason clinical trials show underwhelming average results.

Measuring What Matters to Patients

The medical definition of osteoarthritis anchors itself in biology, but patients experience the disease through pain, stiffness, and lost function. A systematic review identified 78 different patient-reported outcome measures used in osteoarthritis research. The domains most frequently captured were pain, self-care, mobility, and work capacity. Psychological factors, leisure activities, and daily tasks like cleaning and laundry were poorly covered despite their obvious relevance to quality of life.²⁵ The growing burden falls heavily on working-age adults, not only the elderly, and its economic impact through lost productivity and healthcare costs is climbing worldwide, particularly in lower-income countries.²⁶

Osteoarthritis in Other Species

Osteoarthritis is not a uniquely human condition. Dogs, cats, horses, and other domestic animals develop naturally occurring joint disease that shares key features with the human version, including cartilage loss, osteophyte formation, and pain-related behavior changes. Veterinary osteoarthritis has become a valuable resource for understanding the disease, in part because animals develop it spontaneously and in part because their shorter lifespans allow researchers to observe the full disease arc more quickly than in people.²⁷ The cross-species comparison also reinforces how deeply embedded this disease is in joint biology. Some researchers have even proposed that the cellular processes underlying osteoarthritis are part of an age-related biological program shared across species, rather than simply the result of accumulated mechanical damage over a lifetime.²⁸ If that framing holds up, osteoarthritis is less a breakdown caused by living too long and more a trade-off built into how joints are maintained across the lifespan, one that modern medicine is just beginning to understand well enough to intervene.